On July 9, 2025, KALA BIO, Inc. announced patient enrollment completion in its Phase 2b trial for KPI-012, targeting persistent corneal epithelial defects with 79 participants across 37 sites. They expect to report topline data in Q3 2025, which may support a future FDA application.